685513-97-7

Usage

Uses

Used in Organic Synthesis:
1H-Pyrrolo[2,3-b]pyridine-5-carboxylic acid, 4-chloro-1-[tris(1-methylethyl)silyl]-, methyl ester is used as a protecting group for the carboxylic acid functionality during the synthesis of more complex organic molecules. The tris(1-methylethyl)silyl group can be selectively removed under mild conditions, allowing for further reactions to be carried out on the now unprotected carboxylic acid.
Used in Pharmaceutical Industry:
1H-Pyrrolo[2,3-b]pyridine-5-carboxylic acid, 4-chloro-1-[tris(1-methylethyl)silyl]-, methyl ester is used as a building block or intermediate in the synthesis of pharmaceuticals. Its unique structure and functional groups may contribute to the development of new drugs with potential therapeutic applications. The chloro aromatic compound and carboxylic acid ester groups can be further modified to create derivatives with specific biological activities.
Used in Research and Development:
1H-Pyrrolo[2,3-b]pyridine-5-carboxylic acid, 4-chloro-1-[tris(1-methylethyl)silyl]-, methyl ester is used as a research compound in academic and industrial laboratories. Its synthesis and properties are of interest to chemists studying the reactivity and behavior of complex organic molecules. 1H-Pyrrolo[2,3-b]pyridine-5-carboxylic acid, 4-chloro-1-[tris(1-methylethyl)silyl]-, methyl ester may also serve as a model system for understanding the interactions between different functional groups in organic molecules.

InChI:InChI=1/C18H27ClN2O2Si/c1-11(2)24(12(3)4,13(5)6)21-9-8-14-16(19)15(18(22)23-7)10-20-17(14)21/h8-13H,1-7H3

Upstream product

• 79-22-1 methyl chloroformate 
• 651744-48-8 4-chloro-1-triisopropylsilanyl-1H-pyrrolo[2,3-b]pyridine 
• 13154-24-0 triisopropylsilyl chloride 
• 55052-28-3 4-chloro-7-azaindole 
• 271-63-6 7-Azaindole 

Downstream Products

• 951625-93-7 4-chloro-1H-pyrrolo[2,3-b]pyridine-5-carboxylic acid methyl ester 

Relevant academic research and scientific papers

TAM KINASE INHIBITORS

Described herein are compounds, methods of making such compounds, compositions (e.g., pharmaceutical compositions/medicaments) that include such compounds, and methods of using such compounds to treat diseases, such as cancer.

PYRAZOLOPYRIMIDINES AS INHIBITORS OF GLUCOCORTICOID RECEPTOR TRANSLOCATION

Provided herein are compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful as modulators of Glucocorticoid Receptor (GR) translocation. Furthermore, the subject compounds and compositions are useful for the treatment of diseases involved in the hypothalamic-pituitary-adrenal (HPA) axis.

4-Amino-7-azaindole-5-carboxamide derivatives selectively inhibiting the activity of Janus kinase 1

In the present invention, provided are a 4-amino-7-azaindole-5-carboxamide derivative and the property of the 4-amino-7-azaindole-5-carboxamide for selectively inhibiting the activity of Janus kinase 1 and uses of the 4-amino-7-azaindole-5-carboxamide used as a drug for treating rheumatoid arthritis. For this, provided is a compound of chemical formula 1 or a pharmaceutical acceptable salt thereof.

4-Amino-pyrrolopyridine-5-carboxamide: A novel scaffold for JAK1-selective inhibitors

Despite a high level of interest in selective Janus kinase 1 (JAK1) inhibitors and their potential for the treatment of inflammatory diseases such as rheumatoid arthritis (RA), only a few such inhibitors have been reported to date. In this study, a novel 4-amino-1H-pyrrolo[2,3-b]pyridine-5-carboxamide scaffold was designed through structural modification of the potent JAK1-selective inhibitor, C2-methyl imidazopyrrolopyridine. Among the series studied, the 4-(2-aminoethyl)amino-pyrrolopyridine derivative, 2j, exhibited a significant 24.7-fold JAK1/JAK2 selectivity along with reasonable inhibitory activity against JAK1 (IC50=2.2 μM). The noticeable JAK1-selectivity of 2j was then tackled through a molecular docking study, which showed that the aminoethyl functionality of 2j is well positioned to discriminate the subtle but significant difference in the size of the ligand binding sites between JAK1 and JAK2.

HETEROCYCLIC TYROSINE KINASE INHIBITORS

The present invention provides compounds useful as inhibitors of Tec family kinases, compositions thereof, and methods of using the same. In certain embodiments, the present invention provides pharmaceutical formulations comprising provided compounds. In certain embodiments, the present invention provides a method of decreasing enzymatic activity of a Tec kinase family member. In some embodiments, such methods include contacting a Tec kinase family member with an effective amount of a Tec kinase family member inhibitor. In certain embodiments, the present invention provides a method of treating a disorder responsive to Tec kinase family inhibition in a subject in need thereof.

PYRROLOPYRIDINES AS KINASE INHIBITORS

Compounds of Formula (I) are useful for inhibition of CHK1 and/or CHK2. Methods of using compounds of Formula (I) and stereoisomers and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.Formula, (I).

Synthesis of functionalized 7-azaindoles via directed ortho-metalations

Functionalization at C-5 of 4-fluoro- and 4-chloro-1-triisopropylsilyl-7- azaindole, 1 and 2, respectively, leads to a variety of new substituted 7-azaindole derivatives. We also describe two approaches to introduce functionality at C-6.